Literature DB >> 24678977

Nesfatin-1 correlates with hypertension in overweight or obese Han Chinese population.

Yanyan Zhao1, Xiaojun Ma, Qingzhu Wang, Yingni Zhou, Yuanyuan Zhang, Lina Wu, Hongfei Ji, Guijun Qin, Jieli Lu, Yufang Bi, Guang Ning.   

Abstract

We investigated blood nesfatin-1 levels in hypertension patients. We found that fasting plasma nesfatin-1 levels were significantly higher in hypertension patients than in control groups, especially in overweight/obese hypertension patients (4.5 ± 2.1 versus 3.3 ± 1.1 ng/ml, p < 0.01). Body mass index, systolic blood pressure and diastolic blood pressure were indeed positively correlated with fasting plasma nesfatin-1 levels (r = 0.234, p < 0.05; r = 0.304, p < 0.01; r = 0.251, p < 0.05; r = 0.461, p < 0.01; respectively). Logistic regression analysis revealed that the plasma level of nesfatin-1 could be independent of risk prediction over standard measures (OR = 1.547, 95% CI: 1.153-6.273, p = 0.026). Nesfatin-1 has the incremental contribution to hypertension risk prediction (IDI: 0.014, p = 0.018; NRI: 0.050, p = 0.043). The plasma nesfatin-1 level in hypertension patients with microalbuminuria are significantly higher than those without microalbuminuria patients (6.4 ± 2.1 ng/ml versus 3.9 ± 1.8 ng/ml, p < 0.01). Nesfatin-1 might play an important role in obesity hypertension, and its increase could be a risk factor for obesity-associated hypertension.

Entities:  

Keywords:  Body mass index; Han Chinese; hypertension; nesfatin-1; obesity

Mesh:

Substances:

Year:  2014        PMID: 24678977     DOI: 10.3109/10641963.2014.897722

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  11 in total

1.  Nesfatin-1 and Vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome.

Authors:  Figen Kir Sahin; Serap Baydur Sahin; Ulku Mete Ural; Medine Cumhur Cure; Senol Senturk; Yesim Bayoglu Tekin; Gulsah Balik; Erkan Cure; Suleyman Yuce; Aynur Kirbas
Journal:  Bosn J Basic Med Sci       Date:  2015-07-09       Impact factor: 3.363

Review 2.  Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome.

Authors:  Tuba Tekin; Betul Cicek; Nurefsan Konyaligil
Journal:  Eurasian J Med       Date:  2019-08-19

3.  Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome.

Authors:  Peng Shen; Yingying Han; Bo Cai; Yu Wang
Journal:  Sleep Breath       Date:  2014-07-24       Impact factor: 2.816

Review 4.  Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges.

Authors:  Martha A Schalla; Andreas Stengel
Journal:  Curr Diab Rep       Date:  2019-09-10       Impact factor: 4.810

Review 5.  Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.

Authors:  Sandra Feijóo-Bandín; Diego Rodríguez-Penas; Vanessa García-Rúa; Ana Mosquera-Leal; José Ramón González-Juanatey; Francisca Lago
Journal:  Endocrine       Date:  2015-12-12       Impact factor: 3.633

6.  The Relationship between Nesfatin-1 Levels and SYNTAX Score in Patients with Non-ST Segment Elevation Myocardial Infarction.

Authors:  Mevlüt Serdar Kuyumcu; Aliye Kuyumcu; Çağrı Yayla; Mustafa Bilal Özbay; Sefa Ünal; Burak Açar; Cemil Nural; Almila Şenat; Gülhan Samur
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

7.  Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease.

Authors:  Shimei Ding; Wei Qu; Shuangsuo Dang; Xuan Xie; Jing Xu; Yuhuan Wang; Aiyu Jing; Chunhong Zhang; Junhong Wang
Journal:  Med Sci Monit       Date:  2015-04-04

8.  Serum nesfatin-1 and galanin concentrations in the adult with metabolic syndrome. Relationships to insulin resistance and obesity.

Authors:  Maryam N Alotibi; Amina M Alnoury; Amani M Alhozali
Journal:  Saudi Med J       Date:  2019-01       Impact factor: 1.484

9.  Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level.

Authors:  Shizhan Ma; Shangbin Li; Renjun Lv; Xunyao Hou; Shanjing Nie; Qingqing Yin
Journal:  J Diabetes Investig       Date:  2020-04-28       Impact factor: 4.232

Review 10.  Current Understanding of the Role of Nesfatin-1.

Authors:  Martha A Schalla; Andreas Stengel
Journal:  J Endocr Soc       Date:  2018-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.